Antiproliferative effects of anastrozole on MCF‑7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate

Chen,Rong; Cui,Junwei; Wang,Qinqin; Li,Peng; Liu,Xiaoling; Hu,Hui; Wei,Wei

doi:10.3892/mmr.2015.3427

Antiproliferative effects of anastrozole on MCF‑7 human breast cancer cells in vitro are significantly enhanced by combined treatment with testosterone undecanoate

Authors:
- Rong Chen
- Junwei Cui
- Qinqin Wang
- Peng Li
- Xiaoling Liu
- Hui Hu
- Wei Wei
View Affiliations

Affiliations: Department of Breast Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China
Published online on: March 4, 2015 https://doi.org/10.3892/mmr.2015.3427
Pages: 769-775

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to assess the effects of aromatase inhibitor anastrozole and testosterone undecanoate, separately and in combination, on proliferation and apoptosis in MCF‑7 human breast cancer cells cultured in vitro. The effects of various concentrations of these drugs on the proliferation of MCF‑7 cells were evaluated by CCK8 assay, the levels of cell apoptosis were evaluated by flow cytometry with Annexin‑V/propidium iodide staining and androgen receptor (AR) protein expression was determined by western blot analysis. The results of the CCK8 assay indicated that greater antiproliferative activity was detected in the MCF‑7 cells in the combined treatment groups, compared with those treated with anastrozole or testosterone undecanoate alone. Flow cytometric analysis of apoptosis revealed that treatment with a combination of the two drugs generated a higher percentage of apoptotic cells, particularly when the two drugs were applied for 48 h, compared with single drug treatment. Western blot analysis revealed a significant decrease in AR protein expression in the combined treatment groups compared with MCF7 cells treated with single drugs. The results of the present study provided evidence supporting the potential of a combination of anastrozole and testosterone undecanoate as a novel therapeutic strategy for the treatment of breast cancer. Furthermore, it was demonstrated that the antiproliferative effects of anastrozole were significantly enhanced by combined treatment with testosterone undecanoate via the AR signaling pathway.

View Figures

View References

1	Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology: American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 28:3784–3796. 2010. View Article : Google Scholar : PubMed/NCBI
2	Geisler J, King N, Anker G, et al: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 4:2089–2093. 1998.PubMed/NCBI
3	Wong ST and Goodin S: Overcoming drug resistance in patients with metastatic breast cancer. Pharmacotherapy. 29:954–965. 2009. View Article : Google Scholar : PubMed/NCBI
4	Moy I, Lin Z, Rademaker AW, Reierstad S, Khan SA and Bulun SE: Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness. PLoS One. 8:e775432013. View Article : Google Scholar : PubMed/NCBI
5	Madeira M, Mattar A, Logullo AF, Soares FA and Gebrim LH: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer. BMC Cancer. 13:4252013. View Article : Google Scholar : PubMed/NCBI
6	Lønning PE and Eikesdal HP: Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocr Relat Cancer. 20:R183–R201. 2013. View Article : Google Scholar : PubMed/NCBI
7	Normanno N, Di Maio M, De Maio E, et al: Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer. 12:721–747. 2005. View Article : Google Scholar : PubMed/NCBI
8	Macedo LF, Sabnis GJ, Goloubeva OG and Brodie A: Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 68:3516–3522. 2008. View Article : Google Scholar : PubMed/NCBI
9	Castellano I, Allia E, Accortanzo V, et al: Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat. 124:607–617. 2010. View Article : Google Scholar : PubMed/NCBI
10	Hu R, Dawood S, Holmes MD, et al: Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
11	Agoff SN, Swanson PE, Linden H, Hawes SE and Lawton TJ: Androgen receptor expression in estrogen receptor-negative breast cancer Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol. 120:725–731. 2003. View Article : Google Scholar : PubMed/NCBI
12	Moinfar F, Okcu M, Tsybrovskyy O, et al: Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer. 98:703–711. 2003. View Article : Google Scholar : PubMed/NCBI
13	Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM and Bhargava R: Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 23:205–212. 2010. View Article : Google Scholar
14	Somboonporn W and Davis SR; National Health and Medical Research Council: Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 25:374–388. 2004. View Article : Google Scholar : PubMed/NCBI
15	Nahleh Z: Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol. 4:15–21. 2008. View Article : Google Scholar : PubMed/NCBI
16	Morris KT, Toth-Fejel S, Schmidt J, Fletcher WS and Pommier RF: High dehydroepiandrosterone-sulfate predicts breast cancer progression during new aromatase inhibitor therapy and stimulates breast cancer cell growth in tissue culture: a renewed role for adrenalectomy. Surgery. 130:947–953. 2001. View Article : Google Scholar : PubMed/NCBI
17	Gooren LJ: A ten-year safety study of the oral androgen testosterone undecanoate. J Androl. 15:212–215. 1994.PubMed/NCBI
18	Schubert M, Minnemann T, Hübler D, et al: Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. 89:5429–5434. 2004. View Article : Google Scholar : PubMed/NCBI
19	Saad F, Haider A and Gooren L: Effects of long-term treatment of hypogonadal men with testosterone undecanoate on blood pressure, fasting glucose, HbA1c and C-reactive protein. Endocrine Abstracts. 29:3152012.
20	Peters AA, Buchanan G, Ricciardelli C, et al: Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res. 69:6131–6140. 2009. View Article : Google Scholar : PubMed/NCBI
21	Gonzalez LO, Corte MD, Vazquez J, et al: Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis and expression of metalloproteases and their inhibitors. BMC Cancer. 8:1492008. View Article : Google Scholar
22	Labrie F, Simard J, de Launoit Y, et al: Androgens and breast cancer. Cancer Detect Prev. 16:31–38. 1992.PubMed/NCBI
23	Weigelt B, Mackay A, A’hern R, et al: Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 11:339–349. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hugh J, Hanson J, Cheang MC, et al: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 27:1168–1176. 2009. View Article : Google Scholar : PubMed/NCBI
25	Robinson JL, MacArthur S, Ross-Innes CS, et al: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J. 30:3019–3027. 2011. View Article : Google Scholar : PubMed/NCBI
26	Wang Q, Li W, Zhang Y, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
27	Hu R, Dawood S, Holmes MD, et al: Androgen receptor expression and breast cancer survival in postmenopausal women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
28	Ni M, Chen Y, Lim E, et al: Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 20:119–131. 2011. View Article : Google Scholar : PubMed/NCBI
29	Dimitrakakis C, Jones RA, Liu A and Bondy CA: Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 11:531–535. 2004. View Article : Google Scholar : PubMed/NCBI
30	Santoni G and Farfariello V: TRP channels and cancer: new targets for diagnosis and chemotherapy. Endocr Metab Immune Disord Drug Targets. 11:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kuenen-Boumeester V, Van der Kwast TH, van Putten W, Claassen C, Van Ooijen B and Henzen-Logmans SC: Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer. 52:581–584. 1992. View Article : Google Scholar : PubMed/NCBI
32	Hickey TE, Robinson JL, Carroll JS and Tilley WD: Minireview: The androgen receptor in breast tissues: growth inhibitor, tumorsuppressor, oncogene? Mol Endocrinol. 26:1252–1267. 2012. View Article : Google Scholar : PubMed/NCBI
33	Tokunaga E, Hisamatsu Y, Taketani K, et al: Differential impact of the expression of the androgen receptor by age in estrogen receptor-positive breast cancer. Cancer Med. 2:763–773. 2013. View Article : Google Scholar
34	Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C and Gerald WL: An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 25:3994–4008. 2006. View Article : Google Scholar : PubMed/NCBI
35	Yu Q, Niu Y, Liu N, et al: Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol. 22:1288–1294. 2011. View Article : Google Scholar
36	Campagnoli C, Pasanisi P, Castellano I, Abba C, Brucato T and Berrino F: Postmenopausal breast cancer, androgens, and aromatase inhibitors. Breast Cancer Res Treat. 139:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
37	Liu CQ, Wu SZ, Wang ZD, Lai WY and Sun F: Effect of testosterone on expression of androgen receptor in human monocytic cell line THP-1. Di Yi Jun Yi Da Xue Xue Bao. 24:389–391. 2004.In Chinese. PubMed/NCBI